Advances in Immunotherapy of Malignant Pleural Mesothelioma

Dongying Liao; Yongchao Yu; Qingyun Mei; Ziwei Wang; Xiaojiang Li; Yingjie Jia; Fanming Kong

doi:10.2147/OTT.S317434

Advances in Immunotherapy of Malignant Pleural Mesothelioma

Onco Targets Ther. 2021 Aug 14:14:4477-4484. doi: 10.2147/OTT.S317434. eCollection 2021.

Authors

Dongying Liao^{1

2}, Yongchao Yu^{1

2}, Qingyun Mei^{1

2}, Ziwei Wang^{1

2}, Xiaojiang Li^{1

2}, Yingjie Jia^{1

2}, Fanming Kong^{1

2}

Affiliations

¹ Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Nankai District, Tianjin, 300193, People's Republic of China.
² National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Nankai District, Tianjin, 300193, People's Republic of China.

Abstract

Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.

Keywords: immunotherapy; ipilimumab; malignant pleural mesothelioma; nivolumab; progression.

Publication types

Review

Grants and funding

This work is supported by the National Natural Science Foundation of China (No. 81403220 and No.81904151), Tianjin Health and family planning-high level talent selection and training project, Tianjin Science and Technology Plan Projects (No. 17ZXMFSY00190) and Tianjin Traditional Chinese Medicine Research Project, Tianjin health and family planning commission (No. 2017003).